Zimbabwe Business News API

{
    "totalArticles": 14666,
    "articles": [
        {
            "id": "ff9a0f223b54dd302da8a434ff6e7600",
            "title": "MENA startup funding falls to $48.3 million in March 2026",
            "description": "Investment activity across the Middle East and North Africa’s startup ecosystem slowed sharply in March 2026, with just 17 startups...",
            "content": "Investment activity across the Middle East and North Africa’s startup ecosystem slowed sharply in March 2026, with just 17 startups raising a combined $48.3 million. The figure marks an 85% drop month-on-month and a 62% decline compared to March 2025... [3920 chars]",
            "url": "https://www.wamda.com/2026/04/mena-startup-funding-drops-48-3-million-march-2026",
            "image": "https://cdn.wamda.com/feature-images/0e61871faa6d7b1.jpg",
            "publishedAt": "2026-04-06T02:01:19Z",
            "lang": "en",
            "source": {
                "id": "4d7c980de836abd52d568957ee22a9a5",
                "name": "Wamda",
                "url": "https://www.wamda.com"
            }
        },
        {
            "id": "e0e902f0d0a351e088b97b55379133db",
            "title": "Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Psoriasis Results And NDA Plans",
            "description": "Alumis (ALMS) is back in focus after releasing new Phase 3 ONWARD1 and ONWARD2 data on envudeucitinib for moderate to severe plaque psoriasis, alongside plans for a U.S. FDA New Drug Application.\nSee our latest analysis for Alumis.\nThe latest Phase 3 psoriasis data arrives after a sharp run up in Alumis’s 90 day share price return of 181.23%, while the year to date share price return of 160.97% and 1 year total shareholder return of 132.54% point to strong momentum even with a 13.12% 30 day...",
            "content": "Alumis (ALMS) is back in focus after releasing new Phase 3 ONWARD1 and ONWARD2 data on envudeucitinib for moderate to severe plaque psoriasis, alongside plans for a U.S. FDA New Drug Application.\nThe latest Phase 3 psoriasis data arrives after a shar... [3203 chars]",
            "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/assessing-alumis-alms-valuation-after-positive-phase-3-envud",
            "image": "https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299",
            "publishedAt": "2026-04-06T01:36:44Z",
            "lang": "en",
            "source": {
                "id": "5ad034d710ff74cbf858f6cb83ddc3ca",
                "name": "simplywall.st",
                "url": "https://simplywall.st"
            }
        },
        {
            "id": "e328c7456cef676778b702e3fc1a8d14",
            "title": "How Investors Are Reacting To Avery Dennison (AVY) Expanding Its RFID And Intelligent Label Technologies",
            "description": "Avery Dennison recently reported advances in its RFID and intelligent labeling technologies, aiming to better support global supply chains across multiple industries.\nThis focus on more capable identification solutions underscores how the company is deepening its role in digitizing inventory tracking and materials management worldwide.\nNext, we’ll explore how Avery Dennison’s enhanced RFID capabilities could influence its investment narrative around intelligent label adoption and...",
            "content": "Advertisement\nUnited States\n/\nPackaging\n/\nNYSE:AVY\nHow Investors Are Reacting To Avery Dennison (AVY) Expanding Its RFID And Intelligent Label Technologies\nApril 06, 2026\nAvery Dennison recently reported advances in its RFID and intelligent labeling ... [6606 chars]",
            "url": "https://simplywall.st/stocks/us/materials/nyse-avy/avery-dennison/news/how-investors-are-reacting-to-avery-dennison-avy-expanding-i",
            "image": "https://images.simplywall.st/asset/industry/2042000-choice1-main-header/1585186562856",
            "publishedAt": "2026-04-06T01:36:24Z",
            "lang": "en",
            "source": {
                "id": "5ad034d710ff74cbf858f6cb83ddc3ca",
                "name": "simplywall.st",
                "url": "https://simplywall.st"
            }
        }
    ]
}